Company Description
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like ...
VBI Vaccines, Inc. is a biopharmaceutical company, which engages in the development of vaccines for infectious disease and immuno-oncology. The firm focuses on the prevention and treatment of hepatitis B through its product pipeline, the Sci-B-Vac and VBI-2601. It also develops enveloped virus-like particle (eVLP) platform technology, which allows the development of eVLP vaccines that closely mimic the target virus to elicit a potent immune response. The company was founded on July 9, 2015 is headquartered in Cambridge, MA.
Valuation
Price to Sales Ratio
74.22
Price to Book Ratio
2.79
Enterprise Value to Sales
61.65
Total Debt to Enterprise Value
0.12
Efficiency
Revenue/Employee
17,768.00
Income Per Employee
-438,504.00
Receivables Turnover
17.28
Total Asset Turnover
0.02
Liquidity
Current Ratio
1.57
Quick Ratio
1.54
Cash Ratio
1.49
Profitability
Gross Margin
-310.09
Operating Margin
-2,075.96
Pretax Margin
-2,467.94
Net Margin
-2,467.94
Return on Assets
-42.20
Return on Equity
-58.82
Return on Total Capital
-42.55
Return on Invested Capital
-54.78
Capital Structure
Total Debt to Total Equity
18.47
Total Debt to Total Capital
15.59
Total Debt to Total Assets
13.34
Long-Term Debt to Equity
0.93
Long-Term Debt to Total Capital
0.78
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. Jeffrey R. Baxter | 57 | 2016 | President, Chief Executive Officer & Director |
Mr. Christopher McNulty | 42 | 2018 | CFO & Head-Business Development |
Dr. David Evander Anderson | 49 | 2016 | Chief Scientific Officer |
Dr. Francisco Diaz-Mitoma | 64 | 2016 | Chief Medical Officer |
Ms. Nell Beattie | 31 | 2015 | Director-Corporate Development & IR |
Insider Actions
04/24/2020 |
Perceptive Advisors LLC |
9,090,909 | Acquisition at $1.1 per share. | 9,999,999 |
10/04/2019 |
Francisco Diaz-Mitoma Chief Medical Officer |
40,000 | Acquisition at $0.5 per share. | 20,000 |
09/30/2019 |
Jeffrey R. Baxter CEO, President; Director |
150,000 | Acquisition at $0.5 per share. | 75,000 |
09/30/2019 |
Francisco Diaz-Mitoma Chief Medical Officer |
14,500 | Acquisition at $0.5 per share. | 7,250 |
09/23/2019 |
Perceptive Advisors LLC |
20,000,000 | Acquisition at $0.5 per share. | 10,000,000 |
06/27/2019 |
Francisco Diaz-Mitoma Chief Medical Officer |
8,000 | Acquisition at $1.07 per share. | 8,560 |
06/20/2019 |
Francisco Diaz-Mitoma Chief Medical Officer |
42,000 | Acquisition at $0.89 per share. | 37,380 |
06/20/2019 |
Francisco Diaz-Mitoma Chief Medical Officer |
10,000 | Acquisition at $0.78 per share. | 7,800 |
06/19/2019 |
Jeffrey R. Baxter CEO, President; Director |
144,000 | Acquisition at $0.73 per share. | 105,120 |
06/19/2019 |
Nell Beattie Chief Business Officer |
8,000 | Acquisition at $0.74 per share. | 5,920 |
06/17/2019 |
Perceptive Advisors LLC |
1,000,000 | Acquisition at $0.62 per share. | 620,000 |
06/14/2019 |
Jeffrey R. Baxter CEO, President; Director |
31,250 | Derivative/Non-derivative trans. at $0 per share. | 0 |
06/14/2019 |
David Evander Anderson Chief Scientific Officer |
21,875 | Derivative/Non-derivative trans. at $0 per share. | 0 |
06/14/2019 |
Steven H. Gillis Director |
18,750 | Derivative/Non-derivative trans. at $0 per share. | 0 |
06/14/2019 |
Nell Beattie Chief Business Officer |
6,250 | Derivative/Non-derivative trans. at $0 per share. | 0 |
06/14/2019 |
Michel de Wilde Director |
12,500 | Derivative/Non-derivative trans. at $0 per share. | 0 |
01/31/2019 |
David Evander Anderson Chief Scientific Officer |
25,000 | Award at $0 per share. | 0 |
01/31/2019 |
Avi Mazaltov Head Global MFG&GM-SciVac Ltd. |
90,000 | Award at $0 per share. | 0 |
01/31/2019 |
Nell Beattie Chief Business Officer |
15,000 | Award at $0 per share. | 0 |
01/31/2019 |
Christopher McNulty CFO and Head of BD |
25,000 | Award at $0 per share. | 0 |
MarketWatch News on VBIV
-
A Biotech Pro Bought Up These 3 Stocks
- Barron's Online
-
VBI Vaccines upgraded to strong buy from outperform at Raymond James, price target raised $1 to $9
- Tonya Garcia
-
VBI Vaccines stock price target raised to $5 from $4 at BMO Capital
- Tomi Kilgore
-
VBI Vaccines started at outperform with $3 stock price target at Raymond James
- Tomi Kilgore
-
Tegna, First United, Alico, and Other 13D Filings
- Barron's Online
-
Vintage Capital Takes Bite from Red Robin
- Barron's Online
-
A Biotech Pro Loaded Up on These 2 Stocks
- Barron's Online
-
VBI Vaccines started at outperform with $9 stock price target at Oppenheimer
- Tomi Kilgore
-
VBI Vaccines started at outperform with $11 stock price target at BMO Capital
- Tomi Kilgore
-
Viex Sees Potential in Babcock & Wilcox
- Barron's Online
-
VBI Vaccines started at buy with $7 stock price target at Ladenburg Thalmann
- Tomi Kilgore
-
A year after Lehman collapse, few execs resurface
- Alistair Barr
-
- Barron's Online
-
Paulson Capital declares special 15c cash div
- Heather Wilson
-
Paulson Capital declares special 15c div
- Heather Wilson
-
Paulson Capital div record date on Feb. 10
- Heather Wilson
-
Paulson Capital Q3 rev $4.7M vs $12M
- Heather Wilson
-
Paulson Capital Q2 net loss 8c vs $1.91
- Heather Wilson
-
Paulson Capital Q1 net loss 11c vs $1.73
- Carla Mozee
- Loading more headlines...
Other News on VBIV
-
Why is U.S. vaccine rollout taking longer than expected?
- Seeking Alpha
-
VBI Vaccines updates on the COVID-19 study progress
- Seeking Alpha
-
ACB, APHA among premarket gainers
- Seeking Alpha
-
The world will have to live with COVID forever - Moderna CEO
- Seeking Alpha
-
VBI Vaccines: Time To Meet Guidance
- Seeking Alpha
-
8 Penny Stocks to Avoid in 2021
- InvestorPlace.com
-
Could a COVID vaccine passport be issued in the U.S.?
- Seeking Alpha
-
Israel leads world in COVID vaccinations per capita
- Seeking Alpha
-
VBI Vaccines’ Hep B vaccine goes under review in EU
- Seeking Alpha
-
Will vaccines work against the U.K. coronavirus variant?
- Seeking Alpha
-
VBI Vaccines files US application for HBV vaccine
- Seeking Alpha
-
Vaccine access and distribution a big topic at G20
- Seeking Alpha
- Loading more headlines...